TABLE 1.
Characteristics of Intended (n = 382) and Implemented Management Cohorts (n = 206)
| Characteristic | Median | Range | Intended (n) | Implemented (n) |
| Age (y) | 70.1 | 43.8–95.3 | ||
| Ethnicity/race | ||||
| White American | 333 (87%) | 177 (86%) | ||
| Black or African American | 8 (2%) | 2 (1%) | ||
| Asian American | 10 (3%) | 4 (2%) | ||
| Other | 14 (4%) | 7 (3%) | ||
| Missing data | 17 (5%) | 15 (7%) | ||
| Initial therapy | ||||
| Prostatectomy only | 166 (44%) | 86 (42%) | ||
| Radiotherapy only | 101 (26%) | 50 (24%) | ||
| Prostatectomy and salvage radiotherapy | 115 (30%) | 70 (34%) | ||
| Other prior therapy | ||||
| Local salvage therapy | 56 (15%) | 19 (9%) | ||
| Androgen deprivation therapy | 145 (38%) | 80 (39%) | ||
| Abiraterone/enzalutamide | 11 (3%) | 4 (2%) | ||
| Chemotherapy | 12 (3%) | 3 (1%) | ||
| Bone-targeted treatment | 4 (1%) | 1 (0%) | ||
| Other | 24 (6%) | 3 (1%) | ||
| Gleason score | ||||
| <8 | 237 (62%) | 125 (61%) | ||
| ≥8 | 112 (29%) | 62 (30%) | ||
| Missing data | 33 (9%) | 19 (9%) | ||
| PSA | ||||
| Intended cohort | 1.86 | 0.05–425 | ||
| Implemented cohort | 1.75 | 0.2–425 | ||
| PSA doubling time* | 6.30 | 0.43–5,018 | ||
| <6 mo | 150 (39%) | 83 (40%) | ||
| ≥6 mo | 160 (42%) | 94 (46%) | ||
| Missing data | 72 (19%) | 19 (9%) | ||
| Prior staging examination within 6 mo of 68Ga-PSMA PET | ||||
| Negative for prostate cancer | 101 (26%) | 56 (27%) | ||
| Positive for prostate cancer | 46 (12%) | 24 (12%) | ||
| Equivocal | 25 (7%) | 14 (7%) | ||
| None | 210 (55%) | 112 (54%) |
*
In accordance with Pound et al. (22).